Recruiting
A Study of LY900014 Compared to Insulin Lispro (Humalog) in Adults With Type 1 Diabetes
I8B-FH-ITSD - ClinicalTrials.gov - NCT03952130
The purpose of this study is to see if LY900014 compared to insulin lispro (Humalog), both in combination with insulin glargine or insulin degludec, is safe and effective in participants with type 1 diabetes (T1D).
How long will I be in the trial?
The study will last about 39 weeks and may include up to 19 visits.
Recruiting
A Study of LY900014 Compared to Insulin Lispro (Humalog) in Adults With Type 1 Diabetes
I8B-FH-ITSD - ClinicalTrials.gov - NCT03952130
The purpose of this study is to see if LY900014 compared to insulin lispro (Humalog), both in combination with insulin glargine or insulin degludec, is safe and effective in participants with type 1 diabetes (T1D).
How long will I be in the trial?
The study will last about 39 weeks and may include up to 19 visits.
Key Requirements
Age :
18+
Sex:
All
Key Requirements
Use the following checklist to help determine if this trial may be a good fit for you. Place a checkmark next to each criteria that you successfully meet.
Age
18+
Sex
All
Participants must
Participants must have T1D for at least 1 year prior to screening and continuously using insulin for at least 1 year
Participants must have Hemoglobin A1c (HbA1c) of ≥7.0 and ≤10.0%
Participants must have been treated for at least 90 days prior to screening with either multiple daily injection(s) (MDI) or premixed analog/human insulin regimens at least twice daily
Participants must have body mass index (BMI) of ≤35.0 kilograms per square meter (kg/m2)
Participants must NOT
Participants must not have used other anti-hyperglycemic medications or therapies (inhaled, oral or injectable) except for metformin within 90-days of screening
Participants must not have had more than 1 severe hypoglycemic episode within 6 months of screening
Participants must not have had more than 1 hospitalization related to hyperglycemia or diabetic ketoacidosis within 6 months of screening
Trial Summary
Conditions the trial is for
Type 1 Diabetes
What the trial is testing?
LY900014, Insulin Lispro, Insulin Glargine, Insulin Degludec
Could I receive a Placebo?
no
Enrollment Goal
350
Trial Dates
May 2019 - February 2022
Trial Phase
3
Enter your postal code to find the nearest site
Key Requirements
Use the following checklist to help determine if this trial may be a good fit for you. Place a checkmark next to each criteria that you successfully meet.
Age
18+
Sex
All
Participants must
Participants must have T1D for at least 1 year prior to screening and continuously using insulin for at least 1 year
Participants must have Hemoglobin A1c (HbA1c) of ≥7.0 and ≤10.0%
Participants must have been treated for at least 90 days prior to screening with either multiple daily injection(s) (MDI) or premixed analog/human insulin regimens at least twice daily
Participants must have body mass index (BMI) of ≤35.0 kilograms per square meter (kg/m2)
Participants must NOT
Participants must not have used other anti-hyperglycemic medications or therapies (inhaled, oral or injectable) except for metformin within 90-days of screening
Participants must not have had more than 1 severe hypoglycemic episode within 6 months of screening
Participants must not have had more than 1 hospitalization related to hyperglycemia or diabetic ketoacidosis within 6 months of screening
Trial Summary
Conditions the trial is for
Type 1 Diabetes
What the trial is testing?
LY900014, Insulin Lispro, Insulin Glargine, Insulin Degludec
Could I receive a Placebo?
no
Enrollment Goal
350
Trial Dates
May 2019 - February 2022
Trial Phase
3
Not the right fit? Sign up to receive updates on new trials.
Trial Locations
Hide locations not currently recruiting
Enter your postal code to see sites near you
Type 1 Diabetes Resources
